Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ 9-tetrahydrocannabinol or methanandamide from vehicle

Behavioural Pharmacology

Volumn 22, Issue 5-6, 2011, Pages 480-488

  Wiley, Jenny L ^a,b   Matthew Walentiny, D ^b   Vann, Robert E ^b   Baskfield, Cassandra Y ^b  

^a RTI INTERNATIONAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

9 tetrahydrocannabinol; anandamide; cannabinoids; discriminative stimulus; methanandamide; mouse; rimonabant; sex differences

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; METHANANDAMIDE; PHENCYCLIDINE; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; FEMALE; MALE; MOUSE; NONHUMAN; RODENT;

ANIMALS; ARACHIDONIC ACIDS; CYCLOHEXANOLS; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENERALIZATION, STIMULUS; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; PSYCHOTROPIC DRUGS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SEX FACTORS; TETRAHYDROCANNABINOL;

EID: 80051950901     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328348eced     Document Type: Article

References (59)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, et al. (1994). (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893. (Pubitemid 24219781)
2. Adams IB, Ryan W, Singer M, Razdan RK, Compton DR, Martin BR (1995a). Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci 56:2041-2048.
3. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, et al. (1995b). Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 273:1172-1181.
4. Adams IB, Compton DR, Martin BR (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217. (Pubitemid 28130853)
5. Ahn K, Johnson D, Mileni M, Beidler D, Long J, McKinney M, et al. (2009). Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16:411-420.
6. Balster RL, Prescott WR (1992). Delta-9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62.
7. Barrett RL,Wiley JL, Balster RL, Martin BR (1995). Pharmacological specificity of delta-9-tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl) 118:419-424.
8. Baskfield CY, Martin BR, Wiley JL (2004). Differential effects of delta-9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J Pharmacol Exp Ther 309:86-91. (Pubitemid 38393118)
9. Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR (2002). SR-141716A-induced stimulation of locomotor activity: a structure-activity relationship study. Pharmacol Biochem Behav 74:31-40.
10. Burkey RT, Nation JR (1997). (R)-methanandamide, but not anandamide, substitutes for delta-9-THC in a drug-discrimination procedure. Exp Clin Psychopharmacol 5:195-202. (Pubitemid 27346444)
11. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, et al. (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226. (Pubitemid 23320964)
12. Compton DR, Aceto MD, Lowe J, Martin BR (1996). In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594. (Pubitemid 27168965)
13. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87. (Pubitemid 26374593)
14. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. (2001). Supersensitivity to anandamide and enhanced endogenous canna-binoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371-9376. (Pubitemid 32743923)
15. De Lago E, De Miguel R, Lastres-Becker I, Ramos JA, Fernandez-Ruiz J (2004). Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res 1007:152-159. (Pubitemid 38520183)
16. Deutsch DG, Chin SA (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46: 791-796. (Pubitemid 23272758)
17. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, et al. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75:2434-2444.
18. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, et al. (2001). Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor 'hybrid' ligands. Biochem Biophys Res Commun 281:444-451. (Pubitemid 32928176)
19. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002). Anandamide receptors. Prostaglandins Leukot Essen Fatty Acids 66:377-391. (Pubitemid 34743610)
20. Fride E, Mechoulam R (1993). Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmaco 231:313-314. (Pubitemid 23050919)
21. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR (1992). A comparison of the discriminative stimulus properties of delta-9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharmacol Exp Ther 262:479-486.
22. Houser SJ, Eads M, Embrey JP, Welch SP (2000). Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, delta-9-THC and anandamide. Brain Res 857:337-342. (Pubitemid 30107826)
23. Järbe TUC, Mathis DA (1992). Dissociative and discriminative stimulus functions of cannabinoids/cannabimimetics. In: Murphy L, Bartke A, editors. Marijuana/cannabinoids: neurobiology and neurophysiology. Boca Raton, FL: CRC Press. pp. 425-458.
24. Järbe TU, Lamb RJ, Makriyannis A, Lin S, Goutopoulos A (1998). Delta-9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology (Berl) 140:519-522. (Pubitemid 28566852)
25. Järbe T, Lamb R, Lin S, Makriyannis A (2000). Delta-9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behav Pharmacol 11:81-86. (Pubitemid 30223761)
26. Järbe TU, Lamb RJ, Lin S, Makriyannis A (2001). (R)-methanandamide and delta-9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) 156:369-380. (Pubitemid 32695845)
27. Järbe TU, DiPatrizio NV, Li C, Makriyannis A (2003a). The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 75:809-821. (Pubitemid 37289466)
28. Järbe TU, Lamb RJ, Liu Q, Makriyannis A (2003b). (R)-Methanandamide and delta-9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol 466:121-127. (Pubitemid 36385097)
29. Jä rbe TU, Harris MY, Li C, Liu Q, Makriyannis A (2004). Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacology (Berl), 177, 35-45. (Pubitemid 40109912)
30. Jä rbe TU, Lamb RJ, Liu Q, Makriyannis A (2006a). Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with delta-9-THC or (R)-methanandamide (AM-356). Psychopharmacology (Berl) 188:315-323. (Pubitemid 44387459)
31. Järbe TU, Liu Q, Makriyannis A (2006b). Antagonism of discriminative stimulus effects of delta-9-THC and (R)-methanandamide in rats. Psychopharmacol-ogy (Berl) 184:36-45. (Pubitemid 43005755)
32. Jä rbe TU, Li C, Vadivel SK, Makriyannis A (2008). Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psycho-pharmacology (Berl) 198:467-478.
33. Järbe T, Li C, Liu Q, Makriyannis A (2009). Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. Psychopharmacology 203:229-239.
34. Klausner HA, Dingell JV (1971). The metabolism and excretion of delta-9-tetrahydrocannabinol in the rat. Life Sci 10:49-59.
35. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105:2699-2704. (Pubitemid 351520576)
36. Mansbach RS, Balster RL (1991). Pharmacological specificity of the phencycli-dine discriminative stimulus in rats. Pharmacol Biochem Behav 39:971-975.
37. McMahon LR, Ginsburg BC, Lamb RJ (2008). Cannabinoid agonists differentially substitute for the discriminative stimulus effects of delta-9-tetrahydrocanna-binol in C57BL/6J mice. Psychopharmacology (Berl) 198:487-495. (Pubitemid 351754667)
38. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, et al. (2004). Cyclohexylcarbamic acid 30-or 40-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 47:4998-5008. (Pubitemid 39314898)
39. National Research Council (2003). Guidelines for the care and use of mammals in neuroscience and behavioral research. Washington, D.C: National Academies Press.
40. Panlilio LV, Mazzola C, Medalie J, Hahn B, Justinova Z, Drago F, et al. (2009). Anandamide-induced behavioral disruption through a vanilloid-dependent mechanism in rats. Psychopharmacology (Berl) 203: 529-538.
41. Perio A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrie P (1996). Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65-71. (Pubitemid 26051785)
42. Ryan JW, Banner WK, Wiley JL, Martin BR, Razdan RK (1997). Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J Med Chem 40:3617-3625.
43. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092-1101. (Pubitemid 350166046)
44. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129:227-230. (Pubitemid 30072640)
45. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227. (Pubitemid 24229631)
46. Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, et al. (2007). The endogenous cannabinoid anandamide produces delta-9-tetrahydro- cannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321:370-380. (Pubitemid 46456957)
47. Vann RE, Warner JA, Bushell K, Huffman JW, Martin BR, Wiley JL (2009). Discriminative stimulus properties of delta-9-tetrahydrocannabinol (THC) in C57Bl/6J mice. Eur J Pharmacol 615:102-107.
48. Walentiny DM, Gamage TF, Warner JA, Nguyen TK, Grainger DB, Wiley JL, et al. (2011). The endogenous cannabinoid anandamide shares discriminative stimulus effects with delta-9-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. Eur J Pharmacol 656:63-67.
49. Welch SP, Eads M (1999). Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 848:183-190. (Pubitemid 30001667)
50. Welch SP, Huffman JW, Lowe J (1998). Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286:1301-1308. (Pubitemid 29135543)
51. Wiley JL (1999). Cannabis: discrimination of 'internal bliss'? Pharmacol Biochem Behav 64:257-260. (Pubitemid 29438609)
52. Wiley J, Balster R, Martin B (1995a). Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 276:49-54.
53. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR (1995b). Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676.
54. Wiley JL, Huffman JW, Balster RL, Martin BR (1995c). Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocanna- binol in rhesus monkeys. Drug Alcohol Depend 40:81-86.
55. Wiley JL, Lowe JA, Balster RL, Martin BR (1995d). Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.
56. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin BR (1997). Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in Rhesus monkeys. Pharmacol Biochem Behav 58:1139-1143. (Pubitemid 28108227)
57. Wiley JL, Ryan WJ, Razdan RK, Martin BR (1998). Evaluation of cannabimimetic effects of structural analogs of anandamide in rats. Eur J Pharmacol 355:113-118. (Pubitemid 28404692)
58. Wiley JL, LaVecchia KL, Karp NE, Kulasegram S, Mahadevan A, Razdan RK, et al. (2004). A comparison of the discriminative stimulus effects of delta-9-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clin Psychopharmacol 12:173-179. (Pubitemid 38988713)
59. Zygmunt PM, Peterson J, Andersson DA, Chuang HH, Sorgard M, DiMarzo V, et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457. (Pubitemid 29361798)